AU2013218119A1 - Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes - Google Patents
Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes Download PDFInfo
- Publication number
- AU2013218119A1 AU2013218119A1 AU2013218119A AU2013218119A AU2013218119A1 AU 2013218119 A1 AU2013218119 A1 AU 2013218119A1 AU 2013218119 A AU2013218119 A AU 2013218119A AU 2013218119 A AU2013218119 A AU 2013218119A AU 2013218119 A1 AU2013218119 A1 AU 2013218119A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- denotes
- tautomers
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000000707 stereoselective effect Effects 0.000 title claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title description 9
- 238000003786 synthesis reaction Methods 0.000 title description 9
- CGBQPXGVSMMBHA-UHFFFAOYSA-N 9-hydroxy-1,4-diazaspiro[5.5]undecan-5-one Chemical class C1CC(O)CCC21C(=O)NCCN2 CGBQPXGVSMMBHA-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000000543 intermediate Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 101000596532 Homo sapiens Neuronal vesicle trafficking-associated protein 2 Proteins 0.000 claims description 2
- 102100035069 Neuronal vesicle trafficking-associated protein 2 Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 6
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YVHYGXQIVMKZPL-UHFFFAOYSA-N 1-(2,2,2-trifluoroacetyl)-1,4-diazaspiro[5.5]undecane-5,9-dione Chemical compound FC(F)(F)C(=O)N1CCNC(=O)C11CCC(=O)CC1 YVHYGXQIVMKZPL-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- WDWUSIRRAZAUFK-UHFFFAOYSA-N 9-(2,2,2-trifluoroacetyl)-1,4-dioxa-9,12-diazadispiro[4.2.5^{8}.2^{5}]pentadecan-13-one Chemical compound FC(F)(F)C(=O)N1CCNC(=O)C11CCC2(OCCO2)CC1 WDWUSIRRAZAUFK-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000011916 stereoselective reduction Methods 0.000 description 2
- IPSGFPBMDIFDNY-UHFFFAOYSA-N tert-butyl 5,9-dioxo-1-(2,2,2-trifluoroacetyl)-1,4-diazaspiro[5.5]undecane-4-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCN(C(=O)C(F)(F)F)C11CCC(=O)CC1 IPSGFPBMDIFDNY-UHFFFAOYSA-N 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- YYASPOXTFKKZBS-UHFFFAOYSA-N 1,4-dioxa-9,12-diazadispiro[4.2.5^{8}.2^{5}]pentadecan-13-one Chemical compound O=C1NCCNC11CCC2(OCCO2)CC1 YYASPOXTFKKZBS-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- PVDUVJLKEFDGNP-UHFFFAOYSA-N C1CCCCC1.CC1OCCOC1 Chemical compound C1CCCCC1.CC1OCCOC1 PVDUVJLKEFDGNP-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- CXADQLLYLMBGTG-UHFFFAOYSA-N acetonitrile;1,4-dioxane Chemical compound CC#N.C1COCCO1 CXADQLLYLMBGTG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- VMVNZNXAVJHNDJ-UHFFFAOYSA-N methyl 2,2,2-trifluoroacetate Chemical compound COC(=O)C(F)(F)F VMVNZNXAVJHNDJ-UHFFFAOYSA-N 0.000 description 1
- YXRPHMVUMUKKOS-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine;pyridine Chemical compound C1=CC=NC=C1.CN(C)C1=CC=NC=C1 YXRPHMVUMUKKOS-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
- -1 trifluoroacetylimidazole anhydride Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12154688.1 | 2012-02-09 | ||
| EP12154688 | 2012-02-09 | ||
| PCT/EP2013/052287 WO2013117568A1 (de) | 2012-02-09 | 2013-02-06 | Verfahren zur stereoselektiven synthese von 1,4-geschützten 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013218119A1 true AU2013218119A1 (en) | 2014-07-17 |
Family
ID=47678813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013218119A Abandoned AU2013218119A1 (en) | 2012-02-09 | 2013-02-06 | Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8629146B2 (enExample) |
| EP (1) | EP2812317B1 (enExample) |
| JP (1) | JP6105631B2 (enExample) |
| KR (1) | KR20140128318A (enExample) |
| CN (1) | CN104080775A (enExample) |
| AU (1) | AU2013218119A1 (enExample) |
| BR (1) | BR112014019196A8 (enExample) |
| CA (1) | CA2862520A1 (enExample) |
| CL (1) | CL2014001823A1 (enExample) |
| EA (1) | EA201400882A1 (enExample) |
| IL (1) | IL233370A (enExample) |
| MX (1) | MX2014009033A (enExample) |
| PH (1) | PH12014501760B1 (enExample) |
| WO (1) | WO2013117568A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| IL164167A0 (en) | 2002-03-30 | 2005-12-18 | Boehringer Ingelheim Pharma | 4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors |
| AU2006326157A1 (en) | 2005-12-12 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP2289881A1 (de) | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
| WO2012104206A1 (de) * | 2011-02-01 | 2012-08-09 | Boehringer Ingelheim International Gmbh | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung |
-
2013
- 2013-02-06 WO PCT/EP2013/052287 patent/WO2013117568A1/de not_active Ceased
- 2013-02-06 CN CN201380006918.0A patent/CN104080775A/zh active Pending
- 2013-02-06 EP EP13703045.8A patent/EP2812317B1/de active Active
- 2013-02-06 MX MX2014009033A patent/MX2014009033A/es not_active Application Discontinuation
- 2013-02-06 BR BR112014019196A patent/BR112014019196A8/pt not_active IP Right Cessation
- 2013-02-06 JP JP2014556029A patent/JP6105631B2/ja active Active
- 2013-02-06 AU AU2013218119A patent/AU2013218119A1/en not_active Abandoned
- 2013-02-06 KR KR1020147021922A patent/KR20140128318A/ko not_active Withdrawn
- 2013-02-06 EA EA201400882A patent/EA201400882A1/ru unknown
- 2013-02-06 CA CA2862520A patent/CA2862520A1/en not_active Abandoned
- 2013-02-07 US US13/761,211 patent/US8629146B2/en active Active
-
2014
- 2014-06-25 IL IL233370A patent/IL233370A/en not_active IP Right Cessation
- 2014-07-09 CL CL2014001823A patent/CL2014001823A1/es unknown
- 2014-08-05 PH PH12014501760A patent/PH12014501760B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015506966A (ja) | 2015-03-05 |
| CA2862520A1 (en) | 2013-08-15 |
| WO2013117568A1 (de) | 2013-08-15 |
| KR20140128318A (ko) | 2014-11-05 |
| IL233370A (en) | 2015-04-30 |
| US8629146B2 (en) | 2014-01-14 |
| PH12014501760A1 (en) | 2014-11-10 |
| US20130211081A1 (en) | 2013-08-15 |
| CN104080775A (zh) | 2014-10-01 |
| EP2812317A1 (de) | 2014-12-17 |
| CL2014001823A1 (es) | 2015-03-06 |
| IL233370A0 (en) | 2014-08-31 |
| BR112014019196A8 (pt) | 2017-07-11 |
| EA201400882A1 (ru) | 2015-01-30 |
| PH12014501760B1 (en) | 2014-11-10 |
| JP6105631B2 (ja) | 2017-03-29 |
| BR112014019196A2 (enExample) | 2017-06-20 |
| MX2014009033A (es) | 2014-10-17 |
| EP2812317B1 (de) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004074264A1 (ja) | キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体 | |
| DK2462126T3 (en) | Process for stereoselective synthesis of bicyclic heterocyclic compounds. | |
| CN106146512B (zh) | 依鲁替尼的制备方法 | |
| CN113614069B (zh) | 用于制备(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺或其盐的方法以及使用其制备托法替尼的方法 | |
| AU2013218119A1 (en) | Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes | |
| CN110963959B (zh) | 一种合成n-保护及非保护的3-羟基-4,4-二甲基哌啶的制备方法 | |
| JP2011522042A (ja) | タダラフィルの製造方法 | |
| CN114539133B (zh) | 一种制备普芦卡必利中间体1-(3-甲氧基丙基)-4-哌啶胺的方法 | |
| CN115521317B (zh) | 一种制备纳呋拉啡中间体的方法 | |
| JPWO2008087736A1 (ja) | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 | |
| CN109053771B (zh) | 一种托法替布的有关物质及其制备方法和应用 | |
| CN115703733A (zh) | 一种普芦卡必利中间体的制备方法 | |
| US9908858B2 (en) | Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus | |
| US20100174073A1 (en) | Process for the preparation of alfuzosin and salts thereof | |
| CN116348470A (zh) | 八氢噻吩并喹啉化合物的制造方法和其制造中间体 | |
| CN114105961A (zh) | 一种ido1抑制剂(ly-3381916)制备方法 | |
| KR101421032B1 (ko) | (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법 | |
| CN113896730A (zh) | 一种枸橼酸托法替布及其中间体的制备方法 | |
| CN114591220A (zh) | 一种普芦卡必利中间体1-(3-甲氧基丙基)-4-哌啶胺的制备方法 | |
| WO2019207494A1 (en) | Method for the preparation of pimavanserin base | |
| NO820073L (no) | Fremgangsmaate for fremstilling av 4-aminobutyramider | |
| JP2009256316A (ja) | β−ヒドロキシ−γ−ブチロラクトンの製造方法 | |
| WO2003059883A1 (en) | (4-oxopiperidin-1-yl)benzoic acid derivatives and process for their preparation | |
| AU2005252112A1 (en) | Method for producing acetamidopyrrolidine derivative and intermediate compound thereof | |
| HK1099006A (en) | Method for producing acetamidopyrrolidine derivative and intermediate compound thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |